Teriparatide Reduces Bone Microdamage Accumulation in Postmenopausal Women Previously Treated with Alendronate

Abstract

Suppression of bone turnover by bisphosphonates is associated with increased bone microdamage. In this study, 38 postmenopausal women with osteoporosis stopped previous alendronate treatment and switched to teriparatide, whereas 28 were previously treatment naive.

After 24 mo, of teriparatide treatment reduces microdamage accumulation of patients previously treated with alendronate.

Keywords

• Aminobisphosphonates
• Biological Markers
• Bone Remodeling
• Osteoporosis
• Parathyroid Hormone
• Teriparatide